Figure 2.
Estimated prevalence of resistance mutations and 95% confidence bands by drug class and multiclass combinations. Among all ART-experienced patients in care, 2000–2016 (Panels A and B); among ART-experienced patients in care with HIV viremia, 2000–2016 (Panels C and D); among patients in care who initiated ART in 2007 or later, 2007–2016 (Panels E and F).